G Protein-Coupled Receptors (GPCRs) in advancing GPCR-targeted therapies, including the use of agonists, antagonists, biased ...

Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS), a commercial-stage innovative oncology company, today announced that an abstract highlighting interim data from its ongoing Phase 1 clinical trial ...

In the assessment of 12-month price targets, analysts unveil insights for X4 Pharmaceuticals, presenting an average target of ...

The chemokine receptors CCR5 and CXCR4 are the two major coreceptors for HIV entry. Numerous efforts have been made to develop a new class of anti-HIV agents that target these coreceptors as an ...

Stockhead is teaming up with investor relations firm IR Department and broker Morgans to host HealthInvest 2025 in Sydney on ...

BDC-3042 is a proprietary agonist antibody that targets dectin-2, an immune-activating receptor expressed by tumor-associated ...

AbbVie today announced that new data from its early oncology research will be showcased across multiple presentations at the upcoming American Association of Cancer Research (AACR) Annual Meeting, ...

Jan. 16, 2025 — Two new studies have identified a possible way to block the progression of several forms of blood cancer using a drug already in clinical trials ... New Innovative Local ...

This study provides a potentially useful investigation into the positive role of BDNF/TrkB signaling in implanted dental pulp stem cells to enhance dentin regeneration in the context of dental caries.

After hours: March 25 at 7:44:26 PM EDT Loading Chart for CHRS ...

This report demonstrated that the thymus expressed chemokine (TECK), which is expressed in the lamina propria of the small intestine, selectively attracts IgA+ splenic B cells but not IgM+ splenic B ...